Physician profile
Lauren A Fields
NPI 1487195517
$12,329.48
in general payments reported to CMS, 2019-2025
44 companies · $1,485 in 2025
The $1,485 reported for 2025 was more than what 90% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,954 · 2022: $3,078 · 2023: $3,245 · 2024: $2,567 · 2025: $1,485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,256 · Education: $41.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,255.87 |
| Education | $41.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,964.38 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $1,790.41 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $879.03 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Abbott Laboratories | $854.93 | 2021-2025 | Freestyle Libre 3 |
| Abbvie INC. | $632.60 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $623.59 | 2021-2025 | |
| Corcept Therapeutics | $519.99 | 2022-2025 | Korlym |
| Radius Health, INC. | $515.20 | 2022-2025 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $468.79 | 2021-2024 | Lokelma, Farxiga |
| Tandem Diabetes Care, INC. | $364.53 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi-Aventis U.S. LLC | $339.58 | 2021-2024 | |
| Amneal Pharmaceuticals LLC | $329.98 | 2022-2025 | Unithroid |
| Amgen INC. | $285.42 | 2021-2025 | Evenity, Prolia, Tepezza |
| Dexcom, INC. | $255.67 | 2023-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $243.39 | 2023-2025 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascensia Diabetes Care US INC. | $230.27 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $206.61 | 2021-2023 | Steglujan, Steglatro |
| Amarin Pharma, INC. | $186.06 | 2021 | |
| Mannkind Corporation | $181.61 | 2021-2025 | Afrezza |
| Recordati_rare_diseases_inc. | $173.75 | 2023-2025 | Isturisa, Signifor Lar |
| Ascendis Pharma Endocrinology INC | $137.16 | 2025 | Yorvipath |
| Xeris Pharmaceuticals, INC. | $107.91 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Cequr Corporation | $107.43 | 2023-2024 | Cequr Simplicity |
| Alexion Pharmaceuticals, INC. | $106.40 | 2023-2025 | Strensiq |
| Boston Scientific Corporation | $97.63 | 2023-2024 | Watchman Access System, Wavewriter Alpha Prime 16 |
| Insulet Corporation | $96.33 | 2022-2024 | Omnipod |
| Ibsa Pharma INC. | $80.04 | 2022-2025 | Tirosint, Tirosint, Licart |
| Grt US Holding, INC. | $67.05 | 2022 | |
| Medtronic, INC. | $62.79 | 2022-2024 | Minimed 780g |
| Ultragenyx Pharmaceutical INC. | $62.54 | 2021-2023 | |
| Ipsen Biopharmaceuticals, INC | $61.70 | 2021-2022 | |
| Pfizer INC. | $50.56 | 2023-2025 | |
| Sequel Med Tech, LLC | $47.20 | 2025 | Twiist |
| Esperion Therapeutics, INC. | $30.87 | 2021 | |
| Ucb, INC. | $22.27 | 2021 | |
| Antares Pharma, INC. | $20.95 | 2023 | Nocdurna, Tlando, Xyosted |
| Grifols USA, LLC | $18.41 | 2022 | |
| Greenwich Biosciences, INC. | $17.96 | 2021 | |
| Endo Pharmaceuticals INC. | $17.35 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $16.22 | 2021 | |
| Zealand Pharma US, INC. | $15.11 | 2021 | |
| Amryt Pharma Holdings LTD | $14.47 | 2021 | |
| Currax Pharmaceuticals LLC | $13.47 | 2021 | |
| Vistapharm, INC. | $11.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Fields listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.